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Objectives-Previous work has shown that synovial fluid isolated from patients with active rheumatoid arthritis contains soluble (not sedimented by centrifugation at 11600 g for two minutes) and insoluble (sedimented by centrifugation at 11600 g for two minutes) immunoglobulin aggregates that are capable of activating reactive oxidant production by bloodstream neutrophils. The purpose of this study was to determine which of these types of immunoglobulin aggregates activated the secretion of reactive oxygen metabolites and granule enzymes from neutrophils. Methods-Cell free synovial fluid (from patients with rheumatoid arthritis) was added to neutrophils isolated from blood of healthy controls that had been incubated in the presence and absence of granulocyte-macrophage colony stimulating factor (GM-CSF). Reactive oxidant production was measured by luminol chemiluminescence (which detects both intracellular and extracellular oxidant production) and by cytochrome c reduction (which measures superoxide secretion). Results-The soluble aggregates only activated neutrophils that were previously primed, and activated a rapid and transient burst of reactive oxidant secretion. On the other hand, the insoluble aggregates activated primed and unprimed neutrophils with similar efficacy and most of the oxidants generated (especially in unprimed cells) were intracellular. The soluble aggregates, but not the insoluble aggregates, also activated the secretion of myeloperoxidase from neutrophils that had either been pretreated with cytochalasin B or primed with GM-CSF. Conclusion-It is thus proposed that these soluble immunoglobulin aggregates are responsible for activation of the release of tissue damaging granule enzymes and reactive oxidants from primed neutrophils within the rheumatoid joint.
(Ann Rheum Dis 1993; 52: [347] [348] [349] [350] [351] [352] [353] As well as their important role in host defence during the killing of microbial pathogens, inappropriate infiltration and activation of neutrophils in tissues has been implicated in the pathology of inflammatory diseases such as rheumatoid arthritis.' 2 Thus it is envisaged that during active phases of the disease, these cells enter the joint and become activated to secrete their granule enzymes and reactive oxygen metabolites which then attack joint tissues. Indeed, many lines of evidence substantiate this model of tissue damage mediated by neutrophils-for example, neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis exhibit biochemical properties indicating that they have been primed and activated in vivo3-6; synovial fluid contains oxidatively damaged components7 8; and neutrophil derived  enzymes such as myeloperoxidase are detectable within these joints9 'o in a molecular form indicating that degranulation has occurred in parallel with the secretion of reactive oxidants.
If neutrophils within synovial fluid have in fact been activated to secrete these toxic compounds, then there must be neutrophil activating factors present within such joints to account for this activation. Many independent lines of research have implicated large immune complexes, which are present in these joints in large quantities, as the factors that elicit these neutrophil responses.'"'4 Although these insoluble complexes (those sedimented by centrifugation at 11600 g for two minutes) are indeed capable of activating neutrophils in vitro, they are very poor activators of secretion'4 of either reactive oxidants or granule enzymes: most of the reactive oxidant production is intracellular. Hence, such intracellular generation of reactive oxidants that is stimulated by these complexes is unlikely to be of importance in disease pathology.
We have recently shown that synovial fluid isolated from patients with rheumatoid arthritis contains various immunoglobulin aggregates that are capable of activating reactive oxidant generation in neutrophils. ' Some of these are sedimented by centrifugation at 11600 g for two minutes (here defined as insoluble) whereas others are not sedimented under these conditions (here defined as soluble). Curiously, the soluble aggregates only activate neutrophils that have previously been primed in vitro by agents such as granulocyte-macrophage colony stimulating factor or -y-interferon, or in vivo by cytokines, which are known to be present within these joints. The mechanisms of activation of neutrophils by these soluble and insoluble complexes seem to be biochemically distinct because (a) the kinetics of activation are different (the soluble complexes activate a rapid burst of oxidant production, whereas the insoluble complexes activate the cells more slowly); (b) the soluble complexes only activate previously primed cells whereas the insoluble complexes activate primed or unprimed cells with similar efficacy; (c) activation via the soluble complexes is staurosporine insensitive (and hence independent of protein kinase C) whereas that occurring via the insoluble complexes is staurosporine sensitive. In view of these apparently different activation mechanisms, the aim of this work was to determine if these soluble complexes activated the secretion of reactive oxidants and granule enzymes from neutrophils.
Materials and methods

PATIENTS
The group studied (30 patients) were those attending the rheumatology clinics at the Royal Liverpool Hospital. Rheumatoid arthritis was diagnosed from the American Rheumatism Association criteria. The mean age was 55 Chemiluminescence was performed on suspensions of neutrophils (5 X 1 05/ml) suspended in RPMI 1640 medium containing 10 ,uM luminol'8 in a total volume of 1 ml at 37°C. After the addition of stimuli, photon emission was measured at 37°C with a 25 channel LKB Wallac 1251 luminometer. Superoxide production was measured as the rate of superoxide dismutase inhibitable cytochrome c reduction. ' [15] [16] [17] [18] [19] [20] minutes after addition ( fig 1A) . In parallel experiments, we showed that such synovial fluids failed to stimulate the secretion of 02- (fig 1 B) . Because luminol meaures both intracellular and extracellular reactive oxidant production,'8 22 the chemiluminescence shown in fig 1A ( open circles) is due to intracellular oxidant production because this is not accompanied by increases in cytochrome c reduction, which is specific for the secretion of fig 3) . Increasing the concentration of insoluble immunoglobulin aggregates to 50% (v/v), however, altered the kinetics of oxidant production (fig 4) : the maximal rate of luminol chemiluminescence occurred more quickly after stimulation of cells that had previously been primed ( fig 4A) . Furthermore, this higher concentration of When the insoluble immunoglobulin aggregates were tested on unprimed cells, maximal chemiluminescence was found at or above 30% (v/v) and a low 02-secretion was also found at these concentrations ( fig 6) was measured at intervals. fMet-Leu-Phe stimulated a rapid (within 30 seconds) release of this enzyme into the medium. This accounted for 25-35% of the total cellular activity (fig 7) . Whereas the soluble immunoglobulin aggregates also stimulated the release of this enzyme with similar kinetics, the insoluble complexes did not cause degranulation. Increasing the concentration of these insoluble complexes to 25% (v/v) did not lead to detectable enzyme secretion. In the absence of cytochalasin B, both fMet-Leu-Phe and the soluble aggregates stimulated low, but detectable secretion (0-15 (SD 0-05) mU, n=3, and 0-08 (0-03) mU respectively). By contrast, the insoluble aggregates at concentrations of 0 1-50% (v/v) did not stimulate myeloperoxidase release. In the absence of GM-CSF and cytochalasin B all agonists used stimulated insignificant amounts of myeloperoxidase secretion.
Discussion
We have previously shown that the two major neutrophil activating factors within synovial fluid of patients with rheumatoid arthritis are attributable to soluble and insoluble immunoglobulin aggregates.'5 This conclusion has been reached with protein A affinity chromatography, which isolates the insoluble aggregates (which are almost completely recovered in the pellet after centrifugation at 11600 g for two minutes) and also the soluble membrane receptors28 that interact with these immunoglobulin aggregates: perhaps priming alters the affinity (rather than number) of receptors on the plasma membrane, alters their distribution (for example, induces clustering or allows Fc-yRII and III to interact) or affects the mechanisms by which these receptors are coupled to their intracellular signal transduction systems. Further work is necessary to investigate these possibilities. Thirdly, the kinetics of activation, the proportions of intra and extracellular oxidase activity, and the sensitivity of activation to staurosporinel5 indicate distinct activation mechanisms regulating the response of neutrophil to the soluble and insoluble immunoglobulin aggregates. These findings raise the intriguing possibility that the receptors or signal transduction systems activated by these two types of immunoglobulin aggregates are different. This suggests that it may be feasible to block activation of neutrophils via the soluble immunoglobulin aggregates, but leave opsonophagocytosis unaffected. Further work is necessary to establish this possibility, which if realised, should enable us to prevent secretion within the rheumatoid joint (which will prevent tissue damage) but not compromise the ability of these patients to combat bacterial infections.
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